Format

Send to

Choose Destination
Clin Pharmacol Ther. 2010 Jan;87(1):130-3. doi: 10.1038/clpt.2009.197. Epub 2009 Nov 4.

Transporter pharmacogenetics and statin toxicity.

Author information

1
Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. mikko.niemi@helsinki.fi

Abstract

Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. In particular, a common genetic variant of organic anion-transporting polypeptide 1B1 reduces the hepatic uptake of many statins, increasing the risk of statin-induced myopathy. Similarly, genetically impaired adenosine triphosphate (ATP)-binding cassette G2 transporter efflux activity results in a marked increase in systemic exposure to various statins. Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid-lowering therapy.

PMID:
19890253
DOI:
10.1038/clpt.2009.197
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center